Compare Charles River Laboratories Intl. Inc (CRL) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs VNET Group Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $231.94 (market cap $11.14B), while VNET Group Inc trades at $7.91 (market cap $2.21B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 5× VNET Group Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| CRL | VNET | |
|---|---|---|
Market Cap | $11.14B | $2.21B |
Sector | Health | Technology |
52-Week High | $233.60 | $14.03 |
52-Week Low | $145.57 | $7.34 |
Enterprise Value | $14.00B | $5.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
VNET Group trades at $7.72, down 3.62% on the day, with a bearish technical signal and negative earnings momentum after missing Q1 2026 EPS estimates. The company reported a net loss of $256.77 million in 2025, with profitability metrics like ROE at -43.21% indicating financial strain. However, revenue grew to $9.95 billion, and analyst sentiment remains largely positive with a 62.5% buy rating, citing AI-driven demand and new strategic investments from entities linked to CATL.
The outlook is mixed: strong revenue growth and strategic positioning in data centers offer upside, but persistent losses and high debt pose significant risks. Investors should weigh the potential from AI expansion against execution challenges and financial health concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
